A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients With Advanced Solid Tumors and Lymphomas

PURPOSE: Ribociclib (an oral, highly-specific cyclin-dependent kinase 4/6 inhibitor) inhibits tumor growth in preclinical models with intact retinoblastoma protein (Rb+). This first-in-human study investigated the maximum tolerated dose (MTD), recommended dose for expansion (RDE), safety, preliminar...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Clin Cancer Res
Päätekijät: Infante, Jeffrey R., Cassier, Philippe A., Gerecitano, John F., Witteveen, Petronella O., Chugh, Rashmi, Ribrag, Vincent, Chakraborty, Abhijit, Matano, Alessandro, Dobson, Jason R., Crystal, Adam S., Parasuraman, Sudha, Shapiro, Geoffrey I.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2016
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5621377/
https://ncbi.nlm.nih.gov/pubmed/27542767
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-1248
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia